PURPOSE
Federal regulations on promoting objectivity in research apply to human subjects research conducted by or at Cook County Health (CCH). The purpose of this policy is to set forth the requirements for disclosure of and management of Financial Conflicts of Interest (FCOI) in research conducted by or for CCH in order to ensure that all research is free from bias that may result from a FCOI. This policy is intended to supplement and not circumvent other CCH policies.

AFFECTED AREAS
This policy applies to Investigators and any other person responsible for the design, conduct or reporting of human subjects research, regardless of title or position. This includes scientists, trainees, technicians, students, fellows, volunteers, guest researchers and collaborators on research projects in which County employed personnel or contractors are designated key personnel, subcontractors, principal investigators, co-investigators, study coordinators and research assistants.

POLICY
It is CCH policy to promote scientific integrity, patient safety and investigator objectivity in human subject research. Any conflict of interest on the part of Investigators or other members of the research team that has the potential to compromise or can appear to compromise the safety and well-being of human subjects and the integrity of study data and results must be reported and addressed by the CCH IRB. The policy applies at the onset of the award or study (via IRB application) and remains applicable through the life of the funding award or study, whichever is longer.

Anyone planning to conduct or conducting human subjects research at CCH, including Investigators and key study personnel, must disclose financial interests related to the research that exceed $500 within the initial IRB application for the study, including the financial interests of their spouse, domestic partner, and/or dependent child(ren). Investigators and key study personnel must also update the IRB within thirty (30) days of discovering or acquiring a new financial interest or revising an already reported financial interest. Updates to financial interest disclosures must also be made annually, as part of a continuing review application for the study, for certain studies as required by the CCH IRB.

Financial interests disclosed will be reviewed by the CCH IRB in order to determine whether a financial conflict of interest (FCOI) of interest exists. The CCH IRB will implement a Management Plan for any identified FCOI, as appropriate. As applicable, the CCH Research Compliance Officer will provide a FCOI Report to the relevant PHS Awarding Component regarding any financial interest found to constitute a FCOI, including details of the management plan, as outlined below.

Any failure to disclose a potential financial conflict of interest for review to the IRB will be considered a violation of this policy.

DEFINITIONS
A. Financial Conflict of Interest (FCOI): A financial interest of an Investigator or key study personnel that could reasonably appear to directly and significantly affect the design, conduct, or

Policies are updated regularly. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to-date version. Refer to the policy page on the intranet to verify that this is the current version of policy before utilizing.
reporting of a research project, including where the financial interest could reasonably appear to affect the rights and welfare of the human research participants.

B. Financial conflict of interest (FCOI) Report: A report of a financial conflict of interest that is made to a research sponsor (i.e., PHS Awarding Component).

C. Financial interest: Anything of monetary value, whether or not the value is readily ascertainable. Financial interests may include but are not limited to remuneration, compensation, and/or payments for services (e.g., consulting, speaking), royalties, equity interests, intellectual property rights and interests, and industry sponsored or reimbursed travel. For purposes of this policy, CCH generally requires Investigators and key study personnel to disclose financial interests that exceed $500.

D. Institutional Responsibilities: An Investigator’s professional responsibilities conducted on behalf of CCH. This may include but is not limited to activities such as: research, research consultation, teaching, professional practice, institutional committee memberships, and service on panels such as Institutional Review Boards.

E. Investigator: The Project Director or Principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research, which may include, for example, collaborators or consultants.

F. Key study personnel: Individuals who contribute to the scientific development or execution of a research study in a substantive, measurable way, whether or not they receive salaries or compensation under the protocol. This includes but is not limited to: individuals involved in conducting the research with human subjects through an interaction or intervention for research purposes, including participating in the consent process, and those directly involved with recording or processing identifiable private information, including PHI, related to those subjects for the purpose of conducting the research study. Individuals who would not be considered key study personnel include those who will be interacting with research subjects during the course of a research study, but only in his/her regular non-research employment capacity should not be listed as key personnel if the person will perform only genuinely non-collaborative services meriting neither professional recognition nor publication privileges and not associated with individual financial gain, and will not contribute to the design, governance, and/or analysis of the study.

G. Management Plan: A Management Plan is implemented when a Financial Interest is determined to constitute a Financial Conflict of Interest. The CCH IRB must approve and monitor the Management Plan if the research involves human subjects.

H. PD/PI: A Project Director or Principal Investigator

I. Public Health Service (PHS) agency: Includes the Agency for Healthcare Research and Quality (AHRQ), Agency for Toxic Substances and Disease Registry (ATSDR), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health Resources and Services Administration (HRSA), Indian Health Service (HIS), National Institutes of Health (NIH), Office of the Assistant Secretary for Health (OASH), Office of the Assistant Secretary for Preparedness and Response (ASPR), Office of Global Affairs (OG), and Substance Abuse and Mental Health Services Administration (SAMHSA).

J. Research: A systematic investigation, study or experiment designed to develop or contribute to generalizable knowledge relating broadly to public health, including behavioral and social-sciences research. The term encompasses basic and applied research (e.g., a published article, book, or book chapter) and product development (e.g., a diagnostic test or drug). As applicable to CCH, research constitutes 1) any study or investigation approved by the Institutional Review Board (IRB), including those for which the IRB has determined are exempt from review, and/or 2) for which CCH enters into a Clinical Trial Agreement.

K. Retrospective Review: A process utilized to determine (1) if a financial conflict of interest exists in the event of an Investigator’s failure to disclose a financial interest; (2) which is subsequently deemed a FCOI, CCH’s failure to review or manage an identified FCOI, or an Investigator’s failure to comply with a
management plan.

L. **Significant Financial Interest (SFI):** Per the HHS and FDA requirements for PHS studies, a financial interest that consists of one or more of the following interests of the Investigator (or those of the Investigator’s spouse, domestic partner, and/or dependent children) that reasonably appears to be related to the Investigator’s institutional responsibilities with regard to:

1. A publicly traded entity
   a. Remuneration received as of the date of disclosure and in the twelve (12) months preceding the disclosure that exceeds $5,000 in aggregate value. Remuneration includes salary, equity interests, royalties and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship, travel, reimbursement). Equity interests include any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value.

2. A non-publicly traded (private) entity
   a. Remuneration received from the entity as of the date of disclosure and in the twelve (12) months preceding the disclosure, when aggregated, exceeds $5,000, or the Investigator (or the Investigator’s spouse of dependent children) holds any equity interest.

3. Intellectual property rights and interests (e.g., patents, copyrights) upon receipt of any income related to such rights and interest.

4. Reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator so that the exact monetary value may not be readily available) related to their institutional responsibilities.

5. Significant Financial Interest does not include the following:
   a. Salary, royalties, or other remuneration paid by CCH to the Investigator if the Investigator is currently employed or otherwise appointed by CCH, including intellectual property rights assigned to CCH and agreements to share in royalties related to such rights;
   b. Income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control or manage the investment decisions made in these vehicles;
   c. Income from seminars, lectures, or teaching engagements sponsored by a federal, state, or local agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education;
   d. Income from service on advisory committees or review panels sponsored by a federal, state, or local agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education;
   e. Travel that is reimbursed or sponsored by a federal, state, or local agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.

**PROCEDURE/PROCESS**

A. **Disclosure of Financial Interests to the CCH IRB**
   1. All Investigators and key study personnel must disclose whether they (or their spouse, domestic partner, or dependent child(ren)) have a financial interest in any external entity related to the research conducted or their Institutional Responsibilities.
   2. For purposes of this policy, Investigators and key study personnel must disclose to the IRB any financial interests related to the research conducted or their Institutional Responsibilities that consist of:
      a. Remuneration received from an entity in the twelve months preceding the disclosure that exceeds
$500 (including non-CCH-sponsored seminar or lecture income);
  b. Any equity or proprietary interest;
  c. Intellectual property rights and interests over $500; and
  d. Sponsored or reimbursed travel costs, including information regarding the purpose of the trip, the
     identity of the sponsor/organizer, the destination, and the duration.

3. Investigators and key study personnel must initially disclose all relevant financial interests over $500,
   including those of their spouse, domestic partner, and/or dependent child(ren), to the CCH IRB as part
   of the initial IRB application for the research study.

4. Where there is a change to a previously made financial disclosure, Investigators and/or key study
   personnel must submit the change to the CCH IRB within 30 days.

5. Where an Investigator and/or key study personnel discover or acquire a new financial interest related
   to the study that exceeds $500, an update must be provided to the CCH IRB within 30 days.

6. Investigators and key study personnel may also submit annual updates related to their relevant
   financial interests over $500, as required by the CCH IRB (i.e., as part of the Progress Report Form /
   Continuing Review process).

7. Investigators and key study personnel may also need to report their financial interest as part of the
   institutional CCH Dual Employment Survey process (See HR.001.03 Dual Employment), as required by
   the CCH Conflict of Interest policy (See CC.007.01, Conflict of Interest policy), and as part of their
   annual county ethics filing (Cook County Disclosure of Economic Interests).

B. **CCH IRB Review of Reported Financial Interests.**
   1. The IRB shall solicit and review disclosures of financial interests from each Investigator and/or study
      personnel who is planning to conduct or is conducting research.
   2. For each financial interest disclosed, the IRB shall review and consider the following information when
      determining whether a financial conflict of interest (FCOI) exists:
      a. The value of the financial interest disclosed, including whether the financial interest disclosed
         meets the definition of a significant financial interest (SFI), as defined by federal HHS and FDA
         regulations.
      b. Whether the disclosed financial interest could reasonably appear to directly and significantly
         affect the design, conduct, or reporting of a research project;
      c. Whether the financial interest could reasonably appear to affect the rights and welfare of the
         human research participants;
      d. Whether the research is consistent with the core mission and values of CCH;
      e. Whether the potential benefit of the research outweighs the inherent risk of attempting to
         manage the financial interest; and
      f. Whether the financial interest can be managed in a way that ensures the integrity of the research
         and safety of CCH patients and protects the reputation of CCH and its staff.
   3. The IRB review will take into account the nature and extent the individual’s role on a project, the
      nature and extent of their financial interests, and the nature of the research activity under review. The
      IRB may involve the Investigator and/or study personnel, if needed, in the determination of
      whether a financial interest is related to the research conducted.
   4. The IRB will also consider the following when reviewing whether a financial interest is considered a
      FCOI:
      a. FCOIs are per se inevitable, as CCH recognizes that Investigator participation in outside
         professional and commercial activities makes important direct and indirect contributions to the
         vitality and strength of the organization;
      b. A financial interest may still be considered a FCOI if it does not meet the disclosure thresholds
c. FCOIs do not necessarily represent any impropriety when disclosed in advance.

5. The IRB may consult with CCH Compliance and/or Legal (or other CCH Executive Leadership, as needed) when determining whether the financial interest is a FCOI.

6. Where the IRB determines that the interest reported by the Investigator or key study personnel is a FCOI, the IRB will develop and implement a Management Plan that specifies the actions that have been, and will be, taken to manage the FCOI, as detailed in Section C below.

7. For financial interests disclosed as part of the initial IRB application, the review and determinization by the CCH IRB of whether the interest is a FCOI must be made prior to expenditure of funds for the study.

8. For newly disclosed financial interests made by existing Investigators for an existing study (i.e., after submission of IRB Application), the review and determinization by the CCH IRB of whether the interest is a FCOI must be made within sixty (60) days of disclosure.

9. For disclosed financial interests by new Investigators for an existing study (i.e., after submission of IRB Application), the review and determinization by the CCH IRB of whether the interest is a FCOI must be made within sixty (60) days of disclosure.

10. If it is identified that a financial interest that was not disclosed timely by an Investigator or, for whatever reason, was not previously reviewed during an ongoing research project (e.g., was not timely reviewed or reported by a subrecipient), the IRB shall, within 60 days:
   a. Review the disclosure of the financial interest;
   b. Determine whether a FCOI exists;
   c. Implement, on at least an interim basis, a management plan; and
   d. Determine whether the conflict information needs to be reported to the relevant PHS agency.

C. Management of Determined FCOIs.

1. If the CCH IRB determines that a FCOI exists, a Management Plan must be developed, specifying the actions that must be taken to manage such FCOI. Examples of conditions or restrictions that might be imposed to manage a FCOI include, but are not limited to:
   a. Public disclosure of FCOI (e.g., when presenting or publishing the research);
   b. For research projects involving human subjects research, disclosure of FCOI directly to participants;
   c. Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from the FCOI;
   d. Modification of the research plan;
   e. Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;
   f. Reduction or elimination of the financial interest (e.g., sale of an equity interest); or
   g. Severance of relationships that create FCOI.

2. Depending on the nature of the financial interest, the IRB may determine that additional interim measures are necessary with regard to the Investigator or study personnel’s participation in the research project between the date of disclosure and the completion of the review.

3. The IRB may consult with CCH Compliance and/or Legal (or other CCH Executive Leadership, as needed) when designing an appropriate Management Plan.

4. The Management Plan must include the following:
   a. Signed Agreement - The Investigator and/or study personnel must accept the plan in writing. Final IRB approval of the study is contingent upon receipt of this signed agreement.
   b. Assurance of Continued Compliance - The IRB must monitor compliance with the Management
Plan until the research is completed.
c. Notification of Changes - The Investigator and/or study personnel must agree to notify the IRB of any changes, in a timely manner, of financial interests or relationships to determine whether additional oversight is necessary.

5. The IRB must monitor compliance with the Management Plan by the Investigator and/or study personnel on an ongoing basis until the completion of the research project. IRB monitoring of compliance with the Management Plan must be documented.

6. The IRB shall provide regular reports on compliance with Management Plans progress to the Research Compliance Officer, as determined necessary.

D. Investigator Appeal of Determined FCOI.
   1. If an Investigator or study personnel has been determined to have a FCOI by the IRB, they may contact the Research Compliance Officer to request an appeal.
   2. The Research Compliance Officer will coordinate with the Investigator and/or study personnel and the IRB to receive all pertinent documentation and information regarding the FCOI decision and appeal. The Investigator or study personnel shall then appear before the Research Compliance Committee to answer questions and/or to provide additional information.
   3. The Research Compliance Committee shall make the final determination as to whether an actual FCOI exists, based on the information provided. The final determination shall be based on the decision of a majority of the Committee.

E. Reporting of Determined Conflicts to the Research Compliance Officer
   1. Where the CCH IRB determines that the financial interest reported by the Investigator or key study personnel is a FCOI, the IRB will provide all relevant information regarding the identified FCOI to the CCH Research Compliance Officer, including details regarding the Management Plan.
   2. The Research Compliance Officer will review the FCOI and the study information provided to determine whether the conflict is related to PHS-funded research.
   3. The Research Compliance Officer will coordinate with designated officials within CCH to ensure that any required FCOI Report is submitted to the study sponsor or PHS Awarding Component, as required pursuant to the study agreement or contract.

F. Reporting of Determined Conflicts for PHS Funded Research
   1. Where necessary, the Research Compliance Officer will coordinate with designated officials within CCH to ensure that the required FCOI Report is submitted to the PHS Awarding Component, prior to the expenditure of any funds under the research project.
   2. The FCOI Report shall include at least the following:
      a. Project number;
      b. PD/PI or Contact PD/PI if a multiple PD/PI model is used;
      c. Name of the Investigator with the FCOI;
      d. Name of the entity with which the investigator has a FCOI;
      e. Nature of the financial interest (e.g., equity, consulting fee, travel reimbursement, honorarium);
      f. Value of the financial interest (dollar ranges are permissible: $0-$4,999; $5,000-$9,999; $10,000-$19,999; amounts between $20,000-$100,000 by increments of $20,000; amounts above $100,000 by increments of $50,000), or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value;
      g. A description of how the financial interest relates to the PHS-funded research and the basis for the
determination that the financial interest conflicts with such research; and
h. A description of the key elements of the management plan, including:
   i. Role and principal duties of the conflicted investigator in the research project;
   ii. Conditions of the management plan;
   iii. How the management plan is designed to safeguard objectivity in the research project;
   iv. Confirmation of the Investigator's agreement to the management plan;
   v. How the management plan will be monitored to ensure investigator compliance; and
   vi. Other information as needed.

3. In cases in which CCH identifies a FCOI and eliminates it prior to the expenditure of PHS-awarded funds, CCH is not required to submit an FCOI Report to the PHS Awarding Component.

4. For any FCOI that is identified after submission of the initial FCOI report during an ongoing PHS-funded research project (e.g., upon the participation of an investigator who is new to the research project), CCH shall provide to the PHS Awarding Component, within 60 days, a revised FCOI Report regarding the FCOI and ensure that CCH has implemented a management plan.

5. For any FCOI previously reported by CCH with regard to an ongoing PHS-funded research project, CCH shall provide to the PHS Awarding Component an annual FCOI Report that addresses the status of the FCOI and any changes to the management plan for the duration of the PHS-funded research project. The annual FCOI report shall specify whether the financial conflict is still being managed or explain why the FCOI no longer exists.

6. CCH shall provide annual FCOI reports to the PHS Awarding Component for the duration of the project period (including extensions with or without funds) in the time and manner specified by the PHS Awarding Component.

7. In any case in which the HHS determines that a PHS-funded project whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by an investigator with a FCOI that was not managed or reported by CCH as required by this subpart, CCH shall require the Investigator involved to disclose the FCOI in each public presentation of the results of the research and to request an addendum to previously published presentations.

G. Retrospective Review of FCOI.

1. Whenever a FCOI for a study is not identified or managed in a timely manner, the CCH IRB must conduct a retrospective review of the Investigator or study personnel’s research activities to determine if there is bias in the design, conduct, or reporting of the research resulting from the FCOI.
   a. Examples of scenarios that would require a retrospective review include: failure by the investigator to disclose a financial interest that is determined to constitute a FCOI; failure by CCH to review or manage the FCOI; or failure by the Investigator to comply with the Management Plan

2. The retrospective review must be completed within 120 days of determination of the FCOI.

3. The review must include implementing a Management Plan that specifies the actions that have been and will be taken to manage the FCOI moving forward.

4. Documentation of the retrospective review must include, but is not limited to the following key elements:
   a. Project number;
   b. Project title;
   c. PD/PI or contact PD/PI if a multiple PD/PI model is used;
   d. Name of the investigator with the FCOI;
   e. Name of the entity with which the investigator has a financial conflict of interest;
   f. Reason(s) for the retrospective review;
   g. Detailed methodology used for the retrospective review (e.g., methodology of the review process,
h. Findings of the review; and
i. Conclusions of the review.

5. Completion of a retrospective review of the Investigator or study personnel’s activities and research will determine whether any portion of a funded research conducted during a period of noncompliance was biased.

6. The findings of each retrospective review must be reported to the Research Compliance Officer who will determine whether notification needs to be made to a PHS Awarding Component.

7. The Research Compliance Officer will facilitate prompt notification to the PHS Awarding Component, including the submission of a mitigation report, as necessary.

8. The mitigation report must include, at a minimum: the key elements documented in the retrospective review; a description of the impact of the bias on the research project; actions taken by CCH to eliminate or mitigate the effect of the bias (e.g., impact on the research project); extent of harm done, including any qualitative and quantitative data to support any actual or future harm; analysis of whether the research project is salvageable.

9. If appropriate based on the results of the retrospective review, the Research Compliance Officer, in collaboration with designated officials within CCH, shall update the previously submitted FCOI report, specifying the actions that will be taken to manage the FCOI going forward. Thereafter, CCH will submit FCOI reports annually.

10. Depending on the nature of the FCOI, CCH may determine that additional interim measures are necessary regarding the Investigator’s participation in the research project between the date that the FCOI or the Investigator's noncompliance is determined and the completion of the Institution's retrospective review.

H. Public Accessibility of FCOI Policy and Disclosed Financial Interests for PHS Awards or Studies.

1. CCH will post this policy on its website.

2. Upon written request from the public, CCH will make available to the public with five (5) business days certain information related to a FCOI held by an Investigator or study personnel for a PHS award or study.

3. The information will include:
   a. The investigator’s name, title, and role regarding the research project;
   b. Name of the entity in which the financial interest is held;
   c. Nature of the financial interest; and
   d. Approximate dollar value of the financial interest (dollar ranges are permissible) or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measure of fair market value.

4. CCH shall note that the information provided is current as of the date sent and is subject to updates, on at least an annual basis and within 60 days of CCH’s identification of a new FCOI.

5. The Research Compliance Officer shall coordinate requests received from the public and responses, in collaboration with the CCH IRB, the Investigator or study personnel, and other CCH institutional officials (as needed).

I. Sub-Recipient Responsibilities.

1. If CCH carries out PHS-funded research through a subrecipient (e.g., subcontractors or consortium members), CCH must take reasonable steps to ensure that any subrecipient Investigator complies with the applicable federal FCOI requirements by:
   a. Incorporating as part of a written agreement with the subrecipient terms that establish whether
the FCOI policy of CCH or that of the subrecipient will apply to any subrecipient Investigator and study personnel;

b. If the subrecipient’s FCOI policy will apply:
   i. CCH must receive certification, as part of the agreement referenced above, that the subrecipient policy complies with federal FCOI requirements (42 CFR Part 50, Subpart F and 21 CFR Part 54). If the subrecipient cannot provide such certification, the agreement shall state that subrecipient investigators and study personnel are subject to the CCH Research Financial Conflict of Interest Policy for disclosing financial interests that are directly related to the subrecipient’s work for CCH.
   ii. CCH must specify in the agreement the time period(s) for the subrecipient to report all identified FCOI to the CCH Research Compliance Officer and the CCH IRB, which shall be sufficient to enable CCH to provide timely FCOI reports, as necessary, to the PHS Awarding Component;
   c. If the CCH Research Financial Conflict of Interest Policy will apply, the agreement shall specify time period(s) for the subrecipient to submit all disclosures of financial interests to the CCH IRB, which shall be sufficient to enable CCH to comply timely with its review, management, and reporting obligations.

J. Record Keeping.
   1. The CCH IRB will maintain records of all disclosures of financial interests and the IRB’s review of, and response to, such disclosures (whether or not a disclosure resulted in a determination of a FCOI) for:
      a. Three (3) years from the date of submission of the final expenditures report (in the case of grants and cooperative agreements); or
      b. Three (3) years from the final payment (in the case of research contracts), or
      c. Resolution of any government action involving the records, or
      d. As otherwise required by law.
   2. CCH will submit, or permit on site review of, all records pertinent to demonstrate compliance with financial conflict of interest requirements related to research by the sponsor agency.

K. Training.
   1. All Investigators and key study personnel must complete CCH-approved Conflict of Interest training (i.e., CITI Conflict of Interest training) prior to engaging in research and on a periodic basis (at least every four (4) years) after, as required by the IRB.
   2. Investigators and key study personnel must also complete CCH-approved Conflicts of Interest training within thirty (30) days of:
      a. Implementation of this policy;
      b. Revisions to this policy in any manner that impacts the Investigator or study personnel related requirements;
      c. An Investigator or study personnel’s employment by CCH; or
      d. A CCH determination that an Investigator or study personnel is not in compliance with this policy.

L. Sanctions and Related Reporting Responsibilities.
   1. A failure to disclose a financial interest in accordance with this policy shall lead to discipline, up to and including potential termination.
   2. If the failure of an Investigator or study personnel to comply with this policy or a FCOI management plan appears to have biased the design, conduct, or reporting of the PHS-funded research, CCH shall
promptly notify the PHS Awarding Component of the corrective action taken or to be taken.

M. **Confidentiality.**

1. Access to information collected in connection with this policy will be limited to those who have a “need to know” and will be shared in accordance with CCH policy and other legal requirements.

**POLICY UPDATE SCHEDULE**

This policy will be reviewed at least every three (3) years, or more often as appropriate.

**CROSS REFERENCE**

CCH Code of Ethics
CCH Policy: CC.007.01, Conflict of Interest

**REGULATORY REFERENCES**

21 CFR part 54, Financial Disclosure by Clinical Investigators
42 CFR Part 50, Subpart F, Promoting Objectivity in Research
POLICY LEADS
Betty Donaval
Research and Regulatory Affairs, CCH

Nicole Almiro
Chief Compliance and Privacy Officer, CCH

REVIEWERS:
Jeff McCutchan
General Counsel, CCH

APPROVAL PARTY
Israel Rocha, Jr.
Chief Executive Officer, CCH
Electronically Approved
07/27/2022

POLICY HISTORY
Written: June 2022
Approved: 07/27/22
Posted: 07/28/22
Reviewed/Revised: <<insert date>>
Approved: <<insert date>>
Posted: <<insert date>>